How patients have benefited from mouse models of acute promyelocytic leukaemia

Nature Reviews Cancer

Volumn 5, Issue 10, 2005, Pages 821-827

  Lallemand Breitenbach, Valérie ^a   Zhu, Jun ^a,b   Kogan, Scott ^c   Chen, Zhu ^b   De Thé, Hugues ^a,b  

^a CNRS   (France)

^b Laboratory of Molecular Pathology   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC; ARSENIC TRIOXIDE; CYCLIC AMP; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; RETINOIC ACID; THEOPHYLLINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL MODEL; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; LEUKEMIA CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; ANIMAL; DISEASE MODEL; MULTIMODALITY CANCER THERAPY;

ANIMALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE;

EID: 25844504150     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1719     Document Type: Review

References (85)

1. Rangarajan, A. & Weinberg, R. A. Comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Rev. Cancer 3, 952-959 (2003).
2. Vickers, M., Jackson, G. &Taylor, P. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia 14, 722-726 (2000).
3. Gilliland, D. G. & Tallman, M. S. Focus on acute leukemias. Cancer Cell 1, 417-420 (2002).
4. de Thé, H. et al. The PML-RAR α fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675-684 (1991).
5. de Thé, H., Chomienne, C., Lanotte, M., Degos, L. & Dejean, A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a nova transcribed locus. Nature 347, 558-561 (1990).
6. Salomoni, P. & Pandolfi, P. P. The role of PML in tumor suppression. Cell 108, 165-170 (2002).
7. Daniel, M. T. et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82, 1858-1867 (1993).
8. Minucci, S. et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5, 811-820 (2000).
9. Lin, R. & Evans, R. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5, 821-830 (2000).
10. Perez, A. et al. PML/RAR homodimers: distinct binding properties and heteromeric interactions with RXR. EMBO J. 12, 3171-3182 (1993).
11. Kamashev, D., Vitoux, D. & de Thé, H. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J. Exp. Med. 199, 1163-1174 (2004).
12. Brown, D. et al. A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 2551-2556 (1997).
13. Grisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G. & Ley, T. J. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences. Blood 89, 376-387 (1997).
14. He, L. Z. et al. Acute leukemia with promyelocytic features in PML/RARα transgenic mice. Proc. Natl Acad. Sci. USA 94, 5302-5307 (1997).
15. David, G., Terris, B., Marchio, A., Lavau, C. & Dejean, A. The acute promyelocytic leukemia PML-RAR α protein induces hepatic preneoplastic and neoplastic lesions in transgenic mice. Oncogene 14, 1547-1554 (1997).
16. Early, E. et al. Transgenic expression of PML/RARα impairs myelopoiesis. Proc. Natl Acad. Sci. USA 93, 7900-7904 (1996).
17. Westervelt, P. et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARα expression. Blood 102, 1857-1865 (2003).
18. Kogan, S. C. et al. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor α chimeric protein (PMLRARα) to block neutrophil differentiation and initiate acute leukemia. J. Exp. Med. 193, 531-544 (2001).
19. Lane, A. A. & Ley, T. J. Neutrophil elastase cleaves PML-RARα and is important for the development of acute promyelocytic leukemia in mice. Cell 115, 305-318 (2003).
20. He, L. Z. et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nature Genet. 18, 126-135 (1998).
21. He, L. et al. Two critical hits for promyelocytic leukemia. Mol. Cell 6, 1131-1141 (2000).
22. Pollock, J. L. et al. A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 96, 15103-15108 (1999).
23. Rego, E. M. & Pandolfi, P. P. Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders? Trends Mol. Med. 8, 396-405 (2002).
24. Lin, R. J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811-814 (1998).
25. Grignani, F. et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391, 815-818 (1998).
26. Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079-1082 (2002).
27. Meani, N. et al. Molecular signature of retinoic acid treatment in acute promyelocytic leukemia. Oncogene 24, 3358-3368 (2005).
28. Gottifredi, V. & Prives, C. p53 and PML: new partners in tumor suppression. Trends Cell Biol. 11, 184-187 (2001).
29. Bernardi, R. et al. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nature Cell Biol. 6, 665-672 (2004).
30. Bischof, O., Nacerddine, K. & Dejean, A. Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol. Cell. Biol. 25, 1013-1024 (2005).
31. Mallette, F. A., Goumard, S., Gaumont-Leclerc, M. F., Moiseeva, O. & Ferbeyre, G. Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene 23, 91-99 (2004).
32. Insinga, A. et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 23, 1144-1154 (2004).
33. Zhu, J. et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7, 143-153 (2005).
34. Lallemand-Breitenbach, V. et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As(2)O(3)-induced PML or PML/retinoic acid receptor α degradation. J. Exp. Med. 193, 1361-1372 (2001).
35. Chang, C. C., Lin, D. Y., Fang, H. L., Chen, R. H. & Shih, H. M. Daxx mediates the small ubiquitin-like modifier-dependent transcriptional repression of Smad4. J. Biol. Chem. 280, 10164-10173 (2005).
36. Warrell, R., de Thé, H., Wang, Z. & Degos, L. Acute promyelocytic leukemia. New Engl. J. Med. 329, 177-189 (1993).
37. Zhu, J., Chen, Z., Lallemand-Breitenbach, V. & de Thé, H. How acute promyelocytic leukaemia revived arsenic. Nature Rev. Cancer 2, 705-713 (2002).
38. Zheng, P. Z. et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc. Natl Acad. Sci. USA 102, 7653-7658 (2005).
39. Zhu, J. et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 3978-3983 (1997).
40. Muller, S., Matunis, M. J. & Dejean, A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17, 61-70 (1998).
41. Shao, W., Benedetti, L., Lamph, W. W., Nervi, C. & Miller, W. H. J. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR α mutation. Blood 89, 4282-4289 (1997).
42. Zhou, D. C. et al. Frequent mutations in the ligand-binding domain of PML-RAR α after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99, 1356-1363 (2002).
43. Hayakawa, F. & Privalsky, M. L. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5, 389-401 (2004).
44. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins. Proc. Natl Acad. Sci. USA 97, 10173-10178 (2000).
45. Lallemand-Breitenbach, V. et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189, 1043-1052 (1999).
46. Muto, A. et al. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF. Leukemia 15, 1176-1184 (2001).
47. Benoit, G., Roussel, M., Pendino, F., Segal-Bendirdjian, E. & Lanotte, M. Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation. Oncogene 20, 7161-7177 (2001).
48. Zhao, Q. et al. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia 18, 285-292 (2004).
49. Quenech'Du, N., Ruchaud, S., Khelef, N., Guiso, N. & Lanotte, M. A sustained increase in the endogenous level of cAMP reduces the retinoid concentration required for APL cell maturation to near physiological levels. Leukemia 12, 1829-1833 (1998).
50. Ruchaud, S. et al. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc. Natl Acad. Sci. USA 91, 8428-8432 (1994).
51. Guillemin, M. C. et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J. Exp. Med. 196, 1373-1380 (2002).
52. Benoit, G. et al. RAR-in dependent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18, 7011-7018 (1999).
53. Germain, P., Iyer, J., Zechel, C. & Gronemeyer, H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415, 187-192 (2002).
54. Altucci, L. et al. Rexinoid-triggered differentiation and tumours selective apoptosis of AML by protein kinase-A-mediated de-subordination of RXR. Cancer Res. (in press).
55. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 101, 5328-5335 (2004).
56. Warrell, R. P. Jr., He, L. Z., Richon, V., Calleja, E. & Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl Cancer Inst. 90, 1621-1625 (1998).
57. He, L. Z. et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108, 1321-1330 (2001).
58. Insinga, A. et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Med. 11, 71-76 (2005).
59. Nebbioso, A. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med. 11, 77-84 (2005).
60. Ferrara, F. F. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2-7 (2001).
61. Kogan, S. C., Hong, S. H., Shultz, D. B., Privalsky, M. L. & Bishop, J. M. Leukemia initiated by PMLRARα: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood 95, 1541-1550 (2000).
62. Licht, J. D. et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85, 1083-1094 (1995).
63. Jansen, J. H. et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 94, 39-45 (1999).
64. Petti, M. C. et al. Complete remission through blast cell differentiation in PLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood 100, 1065-1067 (2002).
65. Koken, M. H. M. et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 18, 1113-1118 (1999).
66. Kitamura, K. et al. Histone deacetylase inhibitor, but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br. J. Haematol. 108, 696-702 (2000).
67. Jing, Y. et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97, 264-269 (2001).
68. Wang, G. et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol. Oncol. 22, 63-71 (2004).
69. Zhu, Q. et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99, 1014-1022 (2002).
70. Kiyoi, H. et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 11, 1447-1452 (1997).
71. Callens, C. et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia 7, 11543-1160 (2005).
72. Kelly, L. M. et al. PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc. Natl Acad. Sci. USA 99, 8283-8288 (2002).
73. Sohal, J. et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101, 3188-3197 (2003).
74. Zimonjic, D. B., Pollock, J. L., Westervelt, P., Popescu, N. C. & Ley, T. J. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc. Natl Acad. Sci. USA 97, 13306-13311 (2000).
75. Le Beau, M. M., Bitts, S., Davis, E. M. & Kogan, S. C. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood 99, 2985-2991 (2002).
76. Walter, M. J. et al. Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol. Cell. Biol. 24, 10882-10893 (2004).
77. Weinstein, I. B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64 (2002).
78. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
79. Taneja, R. et al. Phosphorylation of activation functions AF-1 and AF-2 of RAR α and RAR γ is indispensable for differentiation of F9 cells on retinoic acid and cAMP treatment. EMBO J. 16, 6452-6465 (1997).
80. Parrella, E. et al. Phosphodiesterase IV inhibition by piclamilast potentiates the cyto-differentiating action of retinoids in myeloid leukemia cells: cross-talk between the cAMP and the retinoic acid signaling pathways. J. Biol. Chem. 279, 42026-42040 (2004).
81. Bernardi, R., Grisendi, S. & Pandolfi, P. P. Modelling haematopoietic malignancies in the mouse and therapeutical implications. Oncogene 21, 3445-3458 (2002).
82. Melnick, A. & Licht, J. D. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167-3215 (1999).
83. Gianni, M. et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91, 4300-4010 (1998).
84. Shao, W. et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J. Natl Cancer Inst. 90, 124-133 (1998).
85. Cheng, G. X. et al. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARα and NPM-RARα. Proc. Natl Acad. Sci. USA 96, 6318-6323 (1999).